Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
about
Second line small molecule therapy options for treating chronic myeloid leukemia.Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.Development of a protease-resistant reporter to quantify BCR-ABL activity in intact cells.Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.
P2860
Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Adverse events associated with ...... t of chronic myeloid leukemia.
@en
type
label
Adverse events associated with ...... t of chronic myeloid leukemia.
@en
prefLabel
Adverse events associated with ...... t of chronic myeloid leukemia.
@en
P2860
P1476
Adverse events associated with ...... t of chronic myeloid leukemia.
@en
P2093
Gioia Colafigli
Matteo Molica
P2860
P304
P356
10.1517/14740338.2016.1145654
P407
P577
2016-01-22T00:00:00Z